Indication for the exougenous surfactant administration to treat neonatal respiratory distress syndrome in the preterm infant: a single-center randomized phase 4 trial based on the comparison of two levels of respiratory severity
Latest Information Update: 19 Aug 2021
Price :
$35 *
At a glance
- Drugs Poractant alfa (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Therapeutic Use
- 19 Aug 2021 New trial record